A case of successful treatment of complete atrioventricular block complicated by sudden arrhythmic death in an elderly patient with post COVID-19 thrombocytopenia

As established today by a number of studies, transferred COVID-19 (even mild) is associated with a high risk of delayed heart damage. Although human coronaviruses are a minor cause of all cases of viral myocarditis, they have been associated with myocarditis in patients of all age groups. Post-COVID-19 myocarditis can be manifested by heart failure, heart rhythm and conduction disorders. A case report of 14-day hospitalization of an 89 y.o. man for a life-threatening myocardial conduction disorder – complete AV block – on the background of a permanent form of Arial fibrillation, accompanied by clinical death of the patient, coagulopathy, nosocomial pneumonia, heart failure and impaired consciousness. During the treatment, which included cardiopulmonary resuscitation, the use of temporary and then permanent pacemaker, antibiotics, levocarnitine, Fondaparinux, blood clot transfusions for profound thrombocytopenia, led to the restoration of heart rhythm and conduction, reduction of heart failure, cure of nosocomial pneumonia and restoration of exercise tolerance. Post- COVID-19 complications are currently still weakly understood and poorly predicted, but their treatment according to the general rules gives positive results. In patients with heparin-induced thrombocytopenia, as in patients with initial thrombocytopenia (including after COVID-19 conditions), it is advisable to use the drug Fondaparinux, which has proven itself in the prevention and treatment of arterial and venous thromboembolism. In the treatment of posthypoxic complications, it is appropriate to use Levocarnitine to correct post-ischemic changes in the myocardium and brain.

1. Siripanthong B., Nazarian S., Muser D., Deo R., Santangeli P., Khanji M.Y. et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17(9):1463–1471. https://doi.org/10.1016/j.hrthm.2020.05.001.

2. Puntmann V.O., Carerj M.L., Wieters I., Fahim M., Arendt C., Hoffmann J. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 ( COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. https://doi.org/10.1001/jamacardio.2020.3557.

3. Errors in statistical numbers and data. JAMA Cardiol. 2020;5(22):1308. https://doi.org/10.1001/jamacardio.2020.4648.

4. Semigolovskii S.Yu., Vavilova T.V., Kashchenko V.A., Semigolovskii S.N., Sapegin A.A. Thrombocytopenia in the structure of hematological disorders in patients of a multiprofile hospital and possible ways to optimize its evaluation. Meditsinskiy sovet = Medical Council. 2017;(20):14–19. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-14-19.

5. Semigolovskiy N.Yu. Clinical validation of a new algorithm for diagnosis and treatment of heparin-induced thrombocytopenia. In: Educational forum “Errors, dangers and complications in anesthesiology and resuscitation”. Moscow, February 15-16, 2019. Мoscow; 2019. (In Russ.)

6. Battistelli S., Genovese A., Gori T. Heparin-induced thrombocytopenia in surgical patients. Am J Surg. 2010;199(1):43–51. https://doi.org/10.1016/j.amjsurg.2009.01.029.

7. Greinacher A., Selleng K. Thrombocytopenia in the Intensive Care Unit Patient. Hematology Am Soc Hematol Educ Program. 2010;2010:135–143. https://doi.org/10.1182/asheducation-2010.1.135.

8. Glance L.G., Blumberg N., Eaton M.P., Lustik S.J., Osler T.M., Wissler R. et al. Preoperative Thrombocytopenia and Postoperative Outcomes after Noncardiac Surgery. Anesthesiology. 2014;120(1):62–75. https://doi.org/10.1097/ALN.0b013e3182a4441f.

9. Salter B.S., Weiner M.W., Trinh M.A., Heller J., Evans A.S., Adams D.H., Fischer G.W. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. J Am Coll Cardiol. 2016;67(21):2519–2532. https://doi.org/10.1016/j.jacc.2016.02.073.

10. Lo G.K., Juhl D., Warkentin T.E., Sigouin C.S., Eichler P., Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–765. https://doi.org/10.1111/j.1538-7836.2006.01787.x.

11. Cuker A., Cines D.B. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209–2218. https://doi.org/10.1182/blood-2011-11-376293.

12. Bokeriya L.A., Chicherin I.N. Heparin-induced thrombocytopenia (current status of the problem). Мoscow: Bakulev Scientific Center for Cardiovascular Surgery of the RAMS; 2007. 96 p. (In Russ.)

13. Warkentin T.E. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(4 suppl. 5):9–16. Available at: https://pubmed.ncbi.nlm.nih.gov/9855179.

14. Szokol J.W. Heparin-induced thrombocytopenia. Semin Cardiothorac Vasc Anesth. 2010;(14):73–74. https://doi.org/10.1177/1089253210362795.

15. LaMuraglia G. M., Houbballah R., Laposata M. The identification and management of heparin-induced thrombocytopenia in the vascular patient. J Vasc Surg. 2012;55(2):562–570. https://doi.org/10.1016/j.jvs.2011.10.082.

16. Linkins L.A., Dans A.L., Moores L.K., Bona R., Davidson B.L., Schulman S., Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl.):e495S-e530S. https://doi.org/10.1378/chest.11-2303.

17. Muslimani A.A., Ricaurte B., Daw H.A. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol. 2007;82(7):652–655. https://doi.org/10.1002/ajh.20849.

18. Watson H., Davidson S., Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159(5):528–540. https://doi.org/10.1111/bjh.12059.

19. Kelton J.G., Arnold D.M., Bates S.M. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med. 2013;368(8):737–744. https://doi.org/10.1056/NEJMct1206642.

20. Kashaev M.S., Farkhutdinov F.F., Taymasova I.A., Safin R.F., Fattakhov R.F., Karimov I.R. et al. The case of deep vein thrombosis treatment against heparinhe-induced thrombocytopenia. Meditsinskiy vestnik Bashkortostana = Bashkortostan Medical Journal. 2017;12(4):79–83. (In Russ.) Available at: https://medvestb.elpub.ru/jour/article/view/131.

21. Barilla D., Martinelli G.L., Cotroneo A., Romano A., Iacopino P. Thrombosis due to Heparin-induced Thrombocytopenia in Cardiac Surgery: is Fondaparinux an Effective Treatment? J Cardiovasc Dis Diagn. 2016;4(3):240. https://doi.org/10.4172/2329-9517.1000240.

22. Kang M., Alahmadi M., Sawh S., Kovacs M.J., Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125(6):924–929. https://doi.org/10.1182/blood-2014-09-599498.

23. Schindewolf M., Steindl J., Beyer-Westendorf J., Schellong S., Dohmen P.M., Brachmann J. et al. Frequent oflabel use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)͡ – findings from the GerHIT multi-centre registry study. Thrombosis Res. 2014;134(1):29–35. https://doi.org/10.1016/j.thromres.2014.03.029.

24. Di Nisio M., Wichers I.M., Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev. 2012;(3):CD004982. Available at: https://pubmed.ncbi.nlm.nih.gov/22419302/

25. Warkentin T.E., Cook R.J., Marder V.J., Sheppard J.I., Moore J.C., Eriksson B.I. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791–3796. https://doi.org/10.1182/blood-2005-05-1938.

26. Grouzi E., Kyriakou E., Panagou I., Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost. 2010;16(6):663–667. https://doi.org/10.1177/1076029609347900.

27. Avdeev S.N., Adamyan L.V., Alekseeva E.I., Bagnenko S.F., Baranov A.A., Baranova N.N. et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Interim recommendations. Version 10 (08.02.2021). Moscow; 2021. (In Russ.) Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf.

28. Semigolovskiy N.Yu., Azanov B.A., Ivanova E.V., Semigolovskiy S.N. Levocarnitine in the syndrome of low cardiac output in patients with acute myocardial infarction, dilated cardiomyopathy, myocardites and pulmonary embolism. Consilium Medicum. 2017;19(5):38–42. (In Russ.) Available at: https://medi.ru/info/13592/